Solid Biosciences Inc. has announced the dosing of the first participant in the Phase 1b FALCON trial, a first-in-human clinical study evaluating SGT-212, an investigational gene therapy for Friedreich's ataxia $(FA)$. SGT-212 utilizes a dual-route administration strategy, combining MRI-guided stereotactic intradentate nuclei infusion to the cerebellar dentate nuclei with an intravenous infusion, aiming to target the neurologic, cardiac, and systemic manifestations of FA. According to the company, intra-procedural MRI imaging confirmed successful targeting and coverage of the intended brain region. Preliminary safety insights are expected to be shared in the coming months, with initial data from the trial anticipated in the second half of 2026, subject to participant enrollment. No trial results have been presented at this time.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solid Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623583-en) on January 12, 2026, and is solely responsible for the information contained therein.